BioCentury | Feb 25, 2019
Company News

Management tracks: Viriom, Matinas, Atreca

Viriom Inc. (San Diego, Calif.) hired Iain Dukes as CEO, a new position at the antiviral company. He is a venture partner at OrbiMed Advisors and serves as chairman of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as...
BioCentury | Feb 24, 2017
Clinical News

Elpida: Ph IIb data

Top-line data from 102 HIV-infected patients naïve to prior antiretroviral therapy and with baseline HIV-1 RNA plasma levels of 4.7-4.8 log10 copies/ml in a double-blind, placebo-controlled, Russian Phase IIb trial showed that once-daily 20 mg...
BioCentury | Jan 20, 2017
Company News

Viriom, NICHD deal

Viriom and NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) partnered to improve the antiviral efficacy of undisclosed Viriom compounds to treat Zika, RSV, HCV, HBV, HIV and other "clinically...
BioCentury | Feb 26, 2016
Financial News

HBV newco Chromis gets $3M seed round

HBV play Chromis Therapeutics Inc. (San Diego, Calif.) raised $3 million in seed financing from Torrey Pines Investment . Chromis' lead candidate is CHR101 , a preclinical HBV treatment targeting covalently closed circular DNA (cccDNA). Torrey Pines...
BioCentury | Jan 14, 2010
Distillery Therapeutics

Indication: Infectious disease

...online Jan. 14, 2010 Patented by The Scripps Research Institute; exclusive licensing option held by Viriome Inc....
BioCentury | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

...and mechanisms of antiviral actions for some of the compounds," said Linda Pullan, CEO of Viriome Inc....
...filed provisional patents covering the findings of the PNAS paper and of the follow-on studies. Viriome...
...Triangle Park, N.C. Varinel Inc. , West Chester, Pa. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Cambridge, Mass. Viriome Inc....
BioCentury | Oct 19, 2009
Company News

Viriom Ltd., Roche deal

Roche granted infectious disease company Viriom exclusive rights to develop and commercialize undisclosed preclinical non-nucleoside reverse transcriptase inhibitors (NNRTIs) to treat HIV/AIDS in Russia, Ukraine, Belarus and Kazakhstan. Roche is eligible for royalties. These will...
BioCentury | Apr 17, 2008
Cover Story

Mining HCV to Sabotage HIV

...an HIV therapeutic. Scripps, which holds the patent on C5A, has out-licensed the peptide to Viriome Inc....
...treatment for HIV, HCV, dengue and other viruses against which the peptide has shown activity. Viriome...
...to advance C5A to the clinic, Chisari said. Gallay said the researchers, in collaboration with Viriome...
BioCentury | Apr 17, 2008
Distillery Therapeutics

This Week in Therapeutics

...cells and macrophages. Future work should determine the HIV envelope lipid to which C5A binds. Viriome Inc....
...for HIV infection. (See Mining HCV to sabotage HIV, page 1.) Patented; C5A licensed to Viriome Inc....
BioCentury | Feb 28, 2008
Distillery Therapeutics

This Week in Therapeutics

...C5A to treat HCV, West Nile virus, dengue, measles, RSV and HIV/AIDS; exclusively licensed to Viriome Inc....
Items per page:
1 - 10 of 10
BioCentury | Feb 25, 2019
Company News

Management tracks: Viriom, Matinas, Atreca

Viriom Inc. (San Diego, Calif.) hired Iain Dukes as CEO, a new position at the antiviral company. He is a venture partner at OrbiMed Advisors and serves as chairman of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as...
BioCentury | Feb 24, 2017
Clinical News

Elpida: Ph IIb data

Top-line data from 102 HIV-infected patients naïve to prior antiretroviral therapy and with baseline HIV-1 RNA plasma levels of 4.7-4.8 log10 copies/ml in a double-blind, placebo-controlled, Russian Phase IIb trial showed that once-daily 20 mg...
BioCentury | Jan 20, 2017
Company News

Viriom, NICHD deal

Viriom and NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) partnered to improve the antiviral efficacy of undisclosed Viriom compounds to treat Zika, RSV, HCV, HBV, HIV and other "clinically...
BioCentury | Feb 26, 2016
Financial News

HBV newco Chromis gets $3M seed round

HBV play Chromis Therapeutics Inc. (San Diego, Calif.) raised $3 million in seed financing from Torrey Pines Investment . Chromis' lead candidate is CHR101 , a preclinical HBV treatment targeting covalently closed circular DNA (cccDNA). Torrey Pines...
BioCentury | Jan 14, 2010
Distillery Therapeutics

Indication: Infectious disease

...online Jan. 14, 2010 Patented by The Scripps Research Institute; exclusive licensing option held by Viriome Inc....
BioCentury | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

...and mechanisms of antiviral actions for some of the compounds," said Linda Pullan, CEO of Viriome Inc....
...filed provisional patents covering the findings of the PNAS paper and of the follow-on studies. Viriome...
...Triangle Park, N.C. Varinel Inc. , West Chester, Pa. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Cambridge, Mass. Viriome Inc....
BioCentury | Oct 19, 2009
Company News

Viriom Ltd., Roche deal

Roche granted infectious disease company Viriom exclusive rights to develop and commercialize undisclosed preclinical non-nucleoside reverse transcriptase inhibitors (NNRTIs) to treat HIV/AIDS in Russia, Ukraine, Belarus and Kazakhstan. Roche is eligible for royalties. These will...
BioCentury | Apr 17, 2008
Cover Story

Mining HCV to Sabotage HIV

...an HIV therapeutic. Scripps, which holds the patent on C5A, has out-licensed the peptide to Viriome Inc....
...treatment for HIV, HCV, dengue and other viruses against which the peptide has shown activity. Viriome...
...to advance C5A to the clinic, Chisari said. Gallay said the researchers, in collaboration with Viriome...
BioCentury | Apr 17, 2008
Distillery Therapeutics

This Week in Therapeutics

...cells and macrophages. Future work should determine the HIV envelope lipid to which C5A binds. Viriome Inc....
...for HIV infection. (See Mining HCV to sabotage HIV, page 1.) Patented; C5A licensed to Viriome Inc....
BioCentury | Feb 28, 2008
Distillery Therapeutics

This Week in Therapeutics

...C5A to treat HCV, West Nile virus, dengue, measles, RSV and HIV/AIDS; exclusively licensed to Viriome Inc....
Items per page:
1 - 10 of 10